By siRNA targeting of KLF9 in Ishikawa cells to mimic the low levels found in EC tumors [23], we found that MET may compensate for the progressive loss of KLF9 in tumor cells by rapidly increasing transcript levels for PGR, PGR-B, and KLF4, all of which exhibit anti-tumor properties. The gene discussed is KLF9; the disease is neoplasm.